Coronary Artery Disease (CAD) - Pipeline Review, H1 2015

1. Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015 (Type, Mode of action, Crop Type and Geography) - Size, Share, Global and China Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020 • TELEPHONE: +1 (855) 711-1555E-MAIL: help@researchbeam.com Published on : Oct 2015

2. Report Overview Summary Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

3. Report Overview The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

4. Report Overview • Reasons to buy • - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • - Develop strategic initiatives by understanding the focus areas of leading companies • - Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) • - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • - Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics • - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

5. Table of Contents Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 11 Therapeutics Development 12 Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 12 Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis 13 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies 14 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Investigation by Universities/Institutes 17 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance 18 Enquire About Report: http://www.researchbeam.com/coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h1-2015-market/enquire-about-report

6. FOR MORE DETAILS Visit us at : www.researchbeam.com/coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h1-2015-market Stay With Us: 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com